Association of apolipoprotein A5 concentration with serum insulin and triglyceride levels and coronary artery disease in Korean men

Atherosclerosis

Volumn 205, Issue 2, 2009, Pages 568-573

  Hyun, Yae Jung ^a,b   Jang, Yangsoo ^a,c   Chae, Jey Sook ^a,b   Kim, Ji Young ^a,b   Paik, Jean Kyung ^b,d   Kim, So Yeon ^b   Yang, Ju Young ^e   Ordovas, Jose M ^f   Ko, Young Guk ^a,c   Lee, Jong Ho ^a,b,d  

^a Yonsei University   (South Korea)

^b Department of Food and Nutrition   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Yonsei University   (South Korea)

^e National Health Insurance Corporation   (South Korea)

^f TUFTS UNIVERSITY   (United States)

Author keywords

Apolipoprotein A5; Coronary artery disease; Insulin; Triglycerides

Indexed keywords

APOLIPOPROTEIN A5; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FATTY ACID BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SOUTH KOREA; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEINS A; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN; KOREA; LIPOPROTEINS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 67651028357     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.12.035     Document Type: Article

References (30)

1. van der Vliet H.N., Sammels M.G., Leegwater A.C., et al. Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem 276 (2001) 44512-44520
2. O'Brien P.J., Alborn W.E., Sloan J.H., et al. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin Chem 51 (2005) 351-359
3. Pennacchio L.A., Olivier M., Hubacek J.A., et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science 294 (2001) 169-173
4. van der Vliet H.N., Schaap F.G., Levels J.H., et al. Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun 295 (2002) 1156-1159
5. Merkel M., Loeffler B., Kluger M., et al. Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280 (2005) 21553-21560
6. Schaap F.G., Rensen P.C., Voshol P.J., et al. ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem 279 (2004) 27941-27947
7. Grosskopf I., Baroukh N., Lee S.J., et al. Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol 25 (2005) 2573-2579
8. Szalai C., Keszei M., Duba J., et al. Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease. Atherosclerosis 173 (2004) 109-114
9. Hsu L.A., Ko Y.L., Chang C.J., et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 185 (2006) 143-149
10. Talmud P.J., Martin S., Taskinen M.R., et al. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res 45 (2004) 750-756
11. Lai C.Q., Corella D., Demissie S., et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study. Circulation 113 (2006) 2062-2070
12. Yamada Y., Kato K., Hibino T., et al. Prediction of genetic risk for metabolic syndrome. Atherosclerosis 191 2 (2007) 298-304
13. Maász A., Kisfali P., Szolnoki Z., Hadarits F., and Melegh B. Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke. J Neurol 255 5 (2008) 649-654
14. Havasi V., Szolnoki Z., Talián G., et al. Apolipoprotein A5 gene promoter region T-1131C polymorphism associates with elevated circulating triglyceride levels and confers susceptibility for development of ischemic stroke. J Mol Neurosci 29 2 (2006) 177-183
15. Maasz A., Kisfali P., Jaromi L., et al. Apolipoprotein A5 gene IVS3 + G476A allelic variant confers susceptibility for development of ischemic stroke. Circ J 72 7 (2008) 1065-1070
16. Priore Oliva C., Pisciotta L., Li Volti G., et al. Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol 25 (2005) 411-417
17. Schaap F.G., Nierman M.C., Berbée J.F., et al. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. J Lipid Res 47 (2006) 2333-2339
18. Dallinga-Thie G.M., van Tol A., Hattori H., et al. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes. Diabetologia 49 (2006) 1505-1511
19. Talmud P.J., Cooper J.A., Hattori H., et al. The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II. Diabetologia 49 (2006) 2337-2340
20. Ishihara M., Kujiraoka T., Iwasaki T., et al. A sandwich enzyme-linked immunosorbent assay for human plasma apolipoprotein A-V concentration. J Lipid Res 46 (2005) 2015-2022
21. Vassen S.F., Schaap F.G., Kuivenhoven J.A., et al. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J Lipid Res 47 (2006) 2064-2070
22. Zhao S.P., Hu S., Li J., et al. Association of human serum apolipoprotein A5 with lipid profiles affected by gender. Clin Chim Acta 376 (2007) 68-71
23. The Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
24. Nowak M., Helleboid-Chapman A., Jakel H., et al. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol 25 (2005) 1537-1548
25. Hirano T., Hayashi T., Adachi M., et al. Marked decrease of apolipoprotein A-V in both diabetic and nondiabetic patients with end-stage renal disease. Metabolism 56 (2007) 462-463
26. Pruneta-Deloche V., Ponsin G., Groisne L., et al. Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients. Atherosclerosis 181 (2005) 403-405
27. Pennacchio L.A., and Rubin E.M. Apolipoprotein A5, a newly identified gene that affects plasma triglyceride levels in humans and mice. Arterioscler Thromb Vasc Biol 23 (2003) 529-534
28. Henneman P., Schaap F.G., Havekes L.M., et al. Plasma apoAV levels are markedly elevated in severe hyper-triglyceridemia and positively correlated with the APOA5 S19W polymorphism. Atherosclerosis 193 (2007) 129-134
29. Alborn W.E., Prince M.J., and Konrad R.J. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes. Clin Chim Acta 378 (2007) 154-158
30. van Dijk K.W., Rensen P.C., Voshol P.J., et al. The role and mode of action of apolipoproteins CIII and AV: synergistic actors in triglyceride metabolism?. Curr Opin Lipidol 15 (2004) 239-246